# Bioactivx Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioactivx-pte

- Industry: Medical Devices & Equipment
- Headquarters: Singapore, Singapore
- Website: www.bioactivx.com
- Total disclosed funding: $1.4M
- Latest round: Seed (Nov 11, 2025)
- Investors on record: 1

## About

Based in Singapore and founded in 2023 by Teo Peili (Co-founder & Director of Technology), Woo Yew Lok (Co-Founder & COO), Mickey Cheong (Co-Founder & COO). Bioactivx Pte Ltd specializes in synthetic regenerative materials aimed at wound care. In August 2026, Bioactivx Pte Ltd raised USD 3 million in pre-series A funding co-led by Cocoon Capital.
Bioactivx® specializes in synthetic, regenerative materials designed for wound care and tissue repair, with a core focus on their flagship product, the Bioactiv® Matrix. This next-generation skin substitute is engineered to expedite the healing of both acute and chronic wounds, such as burns, ulcers, cuts, and abrasions, by promoting skin regeneration and managing inflammation. The biomaterial platform utilizes animal-free, bioinspired technology that mimics natural healing processes, thus addressing the critical need for improved wound recovery solutions. Bioactivx® targets healthcare providers, particularly plastic, reconstructive, and vascular surgeons, who aim to enhance patient outcomes with advanced wound-care solutions. The company is currently preparing for regulatory submission, indicating a strategic focus on markets in North America, Europe, and Asia, where demand for innovative wound care products is growing.
The company's revenue structure revolves around direct partnerships with healthcare facilities and practitioners who incorporate the Bioactiv® Matrix into their treatment protocols. Transactions occur on a B2B basis, wherein hospitals and clinics procure the Bioactiv® Matrix and other future products for patient care. While specific pricing details for their flagship product are not disclosed, the firm is positioned to offer customizable wound care solutions that appeal to various healthcare providers. As the company advances its product line and scales its operations, the focus remains on transforming the wound care landscape through innovative, regenerative medical implants that meet the evolving needs of patients and healthcare professionals alike.
The company will use the August 2026 funding to expand manufacturing, run clinical trials, and develop new wound care products.

## Funding rounds

- Seed, Nov 11, 2025, $1.4M — Cocoon Capital

## Investors

- Cocoon Capital (https://capitalatlas.ai/funds/cocoon-capital) — Seed